Drug intelligence / Profile preview

Hydracarbazine

Development stage: Discontinued
Modality: Small Molecules

Overview

Hydracarbazine is a small molecule, specifically a pyridazine derivative and a hydrazinopyridazine-based diuretic. It was formerly used as an antihypertensive agent for the treatment of arterial hypertension, once marketed in France under the brand name Normatensyl. It is no longer marketed.

Brand names: Normatensyl
Other names: Hidracarbazina6-hydrazinylpyridazine-3-carboxamide3-Pyridazinecarboxamide, 6-hydrazinyl-3-Pyridazinecarboxamide, 6-hydrazino-6-Hydrazinyl-3-pyridazinecarboxamideHydracarbizineTH-2151TH2151TH 2151

Targets

MYH11 (Myosin heavy chain 11)

Beyond the preview

Go deeper on Hydracarbazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hydracarbazine.

Explore the full profile